Investors purchased shares of Amsurg Corp. (NASDAQ:AMSG) on weakness during trading hours on Wednesday. $57.27 million flowed into the stock on the tick-up and $27.97 million flowed out of the stock on the tick-down, for a money net flow of $29.30 million into the stock. Of all companies tracked, Amsurg Corp. had the 11th highest net in-flow for the day. Amsurg Corp. traded down ($1.65) for the day and closed at $62.60

A number of research firms have recently weighed in on AMSG. Zacks Investment Research raised Amsurg Corp. from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a report on Monday, July 11th. Wells Fargo & Co. initiated coverage on Amsurg Corp. in a research note on Tuesday, June 14th. They issued a “market perform” rating for the company. Robert W. Baird reaffirmed a “buy” rating on shares of Amsurg Corp. in a research note on Thursday, June 16th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Amsurg Corp. in a research note on Friday, June 17th. Finally, Bank of America Corp. raised Amsurg Corp. from a “neutral” rating to a “buy” rating and set a $104.00 price target for the company in a research note on Thursday, June 16th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $93.91.

The stock has a market cap of $3.36 billion and a P/E ratio of 18.58. The firm has a 50 day moving average of $74.15 and a 200-day moving average of $74.31.

Amsurg Corp. (NASDAQ:AMSG) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.02. During the same quarter in the previous year, the company posted $0.97 EPS. The firm had revenue of $758.50 million for the quarter, compared to the consensus estimate of $769.88 million. The firm’s revenue was up 21.5% compared to the same quarter last year. On average, equities analysts anticipate that Amsurg Corp. will post $4.33 EPS for the current year.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Amsurg Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,994,029 shares of the company’s stock valued at $227,552,000 after buying an additional 92,088 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Amsurg Corp. by 1,872.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 194,790 shares of the company’s stock valued at $14,804,000 after buying an additional 184,912 shares during the last quarter. Redwood Investments LLC increased its position in Amsurg Corp. by 20.3% in the fourth quarter. Redwood Investments LLC now owns 28,011 shares of the company’s stock valued at $2,129,000 after buying an additional 4,732 shares during the last quarter. US Bancorp DE increased its position in Amsurg Corp. by 30.5% in the fourth quarter. US Bancorp DE now owns 23,339 shares of the company’s stock valued at $1,774,000 after buying an additional 5,461 shares during the last quarter. Finally, Morgan Stanley increased its position in Amsurg Corp. by 115.7% in the fourth quarter. Morgan Stanley now owns 182,105 shares of the company’s stock valued at $13,840,000 after buying an additional 97,682 shares during the last quarter.

AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.